AKBA Stock Overview
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Akebia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.39 |
| 52 Week High | US$2.48 |
| 52 Week Low | US$0.59 |
| Beta | 0.84 |
| 1 Month Change | -18.24% |
| 3 Month Change | -4.14% |
| 1 Year Change | 113.85% |
| 3 Year Change | -51.23% |
| 5 Year Change | -78.78% |
| Change since IPO | -94.79% |
Recent News & Updates
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19
Recent updates
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Another Look At Akebia Therapeutics
Sep 06Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?
Jun 24Akebia wins $40M Department of Veterans Affairs contract
Jun 15FDA accepts Akebia's vadadustat NDA for review
Jun 01Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?
May 26Akebia EPS misses by $0.08, beats on revenue
May 10Akebia highlights late-stage vadadustat kidney disease study results
Apr 28Akebia Therapeutics, Inc. (NASDAQ:AKBA): When Will It Breakeven?
Mar 31Have Insiders Been Selling Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares This Year?
Mar 10Have Insiders Sold Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Recently?
Mar 10Shareholder Returns
| AKBA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.2% | -3.9% | -3.1% |
| 1Y | 113.8% | -1.8% | 20.9% |
Return vs Industry: AKBA exceeded the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: AKBA exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| AKBA volatility | |
|---|---|
| AKBA Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AKBA's share price has been volatile over the past 3 months.
Volatility Over Time: AKBA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 167 | John Butler | www.akebia.com |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
Akebia Therapeutics, Inc. Fundamentals Summary
| AKBA fundamental statistics | |
|---|---|
| Market cap | US$305.68m |
| Earnings (TTM) | -US$51.92m |
| Revenue (TTM) | US$194.62m |
1.5x
P/S Ratio-5.6x
P/E RatioIs AKBA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKBA income statement (TTM) | |
|---|---|
| Revenue | US$194.62m |
| Cost of Revenue | US$39.76m |
| Gross Profit | US$154.86m |
| Other Expenses | US$206.78m |
| Earnings | -US$51.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 79.57% |
| Net Profit Margin | -26.68% |
| Debt/Equity Ratio | -296.7% |
How did AKBA perform over the long term?
See historical performance and comparison